Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to Buy Rating

Zoetis (NYSE:ZTS) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other equities research analysts have also recently commented on the stock. Stifel Nicolaus reduced their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $152.91.

Zoetis Stock Down 0.3%

Shares of NYSE ZTS opened at $124.04 on Friday. The company has a market capitalization of $54.66 billion, a P/E ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The company has a 50 day simple moving average of $123.58 and a 200-day simple moving average of $138.43. Zoetis has a 1 year low of $115.25 and a 1 year high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis will post 6.07 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently modified their holdings of the stock. Tyche Wealth Partners LLC acquired a new position in shares of Zoetis in the fourth quarter worth about $216,000. Patton Fund Management Inc. grew its stake in Zoetis by 24.1% during the 4th quarter. Patton Fund Management Inc. now owns 1,780 shares of the company’s stock valued at $224,000 after acquiring an additional 346 shares in the last quarter. Cove Private Wealth LLC increased its holdings in shares of Zoetis by 12.1% in the 4th quarter. Cove Private Wealth LLC now owns 5,842 shares of the company’s stock valued at $735,000 after purchasing an additional 632 shares during the period. Assetmark Inc. lifted its position in shares of Zoetis by 143.0% in the fourth quarter. Assetmark Inc. now owns 19,862 shares of the company’s stock worth $2,499,000 after purchasing an additional 11,689 shares in the last quarter. Finally, Norris Perne & French LLP MI lifted its position in shares of Zoetis by 24.8% in the fourth quarter. Norris Perne & French LLP MI now owns 63,050 shares of the company’s stock worth $7,933,000 after purchasing an additional 12,534 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.